IceCure Medical highlighted two new peer-reviewed U.S. studies on August 17, 2026. These publications provide clinical validation for the company’s ProSense® cryoablation technology in oncology.
One study details FDA marketing approval for ProSense® regarding early-stage, low-risk breast cancer. The American Society of Breast Surgeons has also included the technology in its clinical guidelines.
A second study explores using cryoablation for metastases in axillary lymph nodes. This research indicates potential applications for the technology beyond primary tumor treatment.
IceCure remains a leader in minimally invasive therapy despite reporting ongoing unprofitability. Financial indicators show a high risk of bankruptcy and significant market skepticism toward growth prospects.